Anderson Cancer Institute Quicklinks   small arrowcontact us  
 
     
fillMUMC HomeHomelineOur ServiceslineFor Patients & CaregiverslineFor Medical ProfessionalslineCancer ResearchlineUnderstanding Cancer
Top Graphic
Gray Graphic
Our Services

World Class

ACI - Services
  Skip Navigation LinksHome > Anderson Cancer Institute > Our Services > Medical Specialties > Surgical Oncology > Christopher Senkowski, M.D.
Change Text Size
  Christopher Senkowski, M.D.


  Christopher Senkowski, M.D., FACS  

General and Oncologic Surgery; GI/Oncologic Surgery; Minimally Invasive Laparoscopic Surgery

Associate Professor, Mercer University
School of Medicine, Department of Surgery

4700 Waters Avenue
Savannah, GA 31404
912-350-2299

Legacy Center
14 Okatie Center Blvd. South
Suite 100
Okatie, SC 29909

To make an appointment:
Phone: 912-350-2299
Fax: 912-350-2298
Web Page: ACI -- Surgical Associates
Memorial Minimally Invasive Surgery


Clinical Expertise: Gallbladder (among the first surgeons in the nation to offer the scarless technique for gallbladder removal), Pancreatic, Liver and Reflux disease, minimally invasive surgical approaches to the Esophagus and Liver (both benign and malignant diseases), Reoperative surgery, Hernia.

Medical Education: Harvard Medical School, Boston

Residency: Mount Sinai Medical Center, New York

Fellowship: Surgical Critical Care/Trauma, Jackson Memorial Hospital, University of Miami School of Medicine

Board Certification: General Surgery, Surgical Critical Care

Professional Affiliations: American College of Surgeons, Society of American Gastrointestinal and Endoscopic Surgeons (SAGES), American Hepato Pancreato Biliary Association (AHPBA), Society of Surgical Oncology's Coding and Reimbursement Committee, American College of Surgeons Oncology Group (ACOSOG), American Association for the Surgery of Trauma, Association of Program Directors in Surgery (APDS)

Research Interests: Acute pancreatitis global consensus definition statement and EBM, ACOSOG E2202, Minimally Invasive Esophagectomy: A Multicenter Feasibility Study, An intergroup randomized phase II study of bevacizumab or cetuximab in combination with gemcitabine and in combination with chemoradiation in patients with completely resected pancreatic carcinoma, Neoadjuvant chemoradiation with oxaliplatin and capecitabine for patients with surgically respectable gastric cancer, Oxaliplatin plus protracted 5 fu and radiation for potentially curable esophageal cancer: A phase II trial with molecular correlates, Phase III randomized double blind study of adjuvant ST1571 versus placebo in patients following the resection of primary gastrointestinal stromal tumors, Flexible transgastric peritoneoscopy: feasibility and applicability in large animal model.

Meet other members of the surgical oncology team.


 
bottom graphic  
© 2012 Memorial University Medical Center

Home | Our Services | For Patients & Caregivers | For Medical Professionals | Cancer Research | Understanding Cancer

Curtis and Elizabeth Anderson Cancer Institute at Memorial University Medical Center: 4700 Waters Avenue, Savannah, GA 31404 - 912-350-8490